ImmunoGen Inc. (IMGN)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

830 WINTER ST WALTHAM, MA 02451

ImmunoGen Inc. discovers and develops therapeutic monoclonal antibodies and novel treatments in the field of oncology. Its lead technology, which it refers to as tumor-activated prodrug, uses antibodies to deliver potent cell-killing agents specifically to cancer cells.

Data as of 2021-05-08 10:29:37 -0400
Market Cap1.466 Billion Shares Outstanding199.942 Million Avg 30-day Volume1.462 Million
P/E Ratio-33.0293 Dividend Yield EPS-0.252
Price/Sales11.08 Debt to Equity3.96 EBITDA-18.792 Million
Price to Book Value16.36 Forward PE-9.57 Enterprise Value1.172 Billion
Total Cash293.856 Million Current Debt122.323 Million Gross Profit132.299 Million
BETA1.44981 52-week High/Low10.88 / 3.38 Next Earnings Date Price to Cash FLow (P/CF) 50.2437
Data provided by IEX Cloud
View SEC Filings from IMGN instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 208 183 13.66% 60 (3.6%) 45 (2.8%) 33.33%
13F shares: 173.482 Million 142.072 Million 22.11% 100.083 Million 78.683 Million 27.2%
% Ownership 89.0979 75.7603 17.6% 51.401 41.958 22.51%
New Positions: 42 25 68.0% 19 5 280.0%
Increased Positions 56 48 16.67% 16 13 23.08%
Closed Positions 18 28 -35.71% 4 8 -50.0%
Reduced Positions 72 68 5.88% 21 21 0.0%
Total Calls 503.152 Thousand 212.249 Thousand 137.06% 75.8 Thousand 21.5 Thousand 252.56%
Total Puts 618.061 Thousand 137.578 Thousand 349.24% 225.9 Thousand 35.6 Thousand 534.55%
PUT/CALL Ratio 1.23 0.65 89.23% 2.98 1.66 79.52%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding IMGN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding IMGN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GOLDBERG MARK ALAN

  • Director
109,876 2021-03-31 5

MITCHELL DEAN J

  • Director
93,774 2021-03-31 5

WINGROVE THERESA SVP OF REGULATORY AFFAIRS

  • Officer
0 2021-02-05 3

ENYEDY MARK J CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
429,017 2021-02-05 2

BERKENBLIT ANNA SVP & CHIEF MEDICAL OFFICER

  • Officer
0 2021-02-05 3

COEN STACY ANN CHIEF BUSINESS OFFICER

  • Officer
0 2021-02-05 3

ALTSCHULLER SUSAN SVP AND CFO

  • Officer
0 2021-02-05 3

LENTINI RENEE V.P.-FIN., PRIN. ACCTG. OFF.

  • Officer
0 2021-02-05 3

FOSTER DAVID G V.P.-FIN., PRIN. ACCTG. OFF.

  • Officer
38,274 2020-12-31 3

RYLL THOMAS VP, TECHNICAL OPERATIONS

  • Officer
80,865 2020-06-30 1

MCCLUSKI STEPHEN C

  • Director
0 2020-06-17 1

WALLACE RICHARD JOHN

  • Director
0 2020-06-17 1

PETERSON KRISTINE

  • Director
0 2020-06-17 1

ARBUCKLE STUART A

  • Director
0 2020-06-17 1

BARROWS CRAIG EXECUTIVE VP, GENERAL COUNSEL

  • Officer
145,275 2020-02-24 0

MCKEE BLAINE H. EVP & CHIEF BUSINESS OFFICER

  • Officer
5,230 2019-07-01 0

GREGORY RICHARD J. EXECUTIVE VP & CSO

  • Officer
199,413 2019-02-22 0

JOHNSTON DAVID BRANNON CHIEF FINANCIAL OFFICER

  • Officer
180,690 2018-06-06 0

JUNIUS DANIEL M

  • Director
184,987 2018-03-16 0

VILLAFRANCA JOSEPH J

  • Director
0 2017-12-31 0

PIEN HOWARD H

  • Director
0 2017-12-31 0

WILLIAMS PETER J. VP, BUSINESS DEVELOPMENT

  • Officer
50,620 2017-02-23 0

LAMBERT JOHN EXECUTIVE VICE PRESIDENT

  • Officer
120,521 2016-11-02 0

POOLE SANDRA EXECUTIVE VP, TECH OPERATIONS

  • Officer
0 2016-10-19 0

MORRIS CHARLES Q EXECUTIVE VP & CDO

  • Officer
0 2016-07-18 0

HARRISON ELLIE VP & CHIEF HR OFFICER

  • Officer
0 2016-07-18 0

ONETTO NICOLE

  • Director
0 2015-11-10 0

O'LEARY JAMES J VICE PRESIDENT

  • Officer
0 2014-07-17 0

PERRY GREGORY D CHIEF FINANCIAL OFFICER

  • Officer
0 2013-09-10 0

SKALETSKY MARK B

  • Director
0 2012-11-13 0

SAYARE MITCHEL

  • Director
383,136 2011-07-29 0

CARTER DAVID WARREN

  • Director
0 2010-11-16 0

CADDEN SUZANNE VP, REGULATORY & QUALITY

  • Officer
0 2009-12-17 0

SAMANA CAPITAL, L.P.

MORTON HOLDINGS, INC.

KORSANT PHILIP B

  • 10% Owner
No longer subject to file 2009-07-31 0

ZIFF ASSET MANAGEMENT LP

PBK HOLDINGS INC

KORSANT PHILIP B

ZBI EQUITIES, L.L.C.

  • 10% Owner
9,046,200 2008-06-20 0

TAGLIAMONTE JOHN VP, BUSINESS DEVELOPMENT

  • Officer
0 2008-06-11 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

MITCHELL DEAN J - Director

2021-04-02 13:01:22 -0400 2021-03-31 A 1,666 a 93,774 direct

GOLDBERG MARK ALAN - Director

2021-04-02 13:02:12 -0400 2021-03-31 A 1,666 a 109,876 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
IMMUNOGEN INC IMGN 2021-05-10 22:15:04 UTC -0.3667 0.4167 1900000
IMMUNOGEN INC IMGN 2021-05-10 21:45:02 UTC -0.3667 0.4167 1900000
IMMUNOGEN INC IMGN 2021-05-10 21:15:02 UTC -0.3667 0.4167 1900000
IMMUNOGEN INC IMGN 2021-05-10 20:45:03 UTC -0.3456 0.3956 1900000
IMMUNOGEN INC IMGN 2021-05-10 20:15:03 UTC -0.3456 0.3956 1900000
IMMUNOGEN INC IMGN 2021-05-10 19:45:03 UTC -0.3456 0.3956 1900000
IMMUNOGEN INC IMGN 2021-05-10 19:15:03 UTC -0.3456 0.3956 1900000
IMMUNOGEN INC IMGN 2021-05-10 18:45:03 UTC -0.304 0.354 1900000
IMMUNOGEN INC IMGN 2021-05-10 18:15:03 UTC -0.304 0.354 1900000
IMMUNOGEN INC IMGN 2021-05-10 17:45:02 UTC -0.304 0.354 1900000
IMMUNOGEN INC IMGN 2021-05-10 17:15:03 UTC -0.304 0.354 1900000
IMMUNOGEN INC IMGN 2021-05-10 16:45:03 UTC -0.304 0.354 1900000
IMMUNOGEN INC IMGN 2021-05-10 16:15:03 UTC -0.304 0.354 1900000
IMMUNOGEN INC IMGN 2021-05-10 15:45:03 UTC -0.304 0.354 1600000
IMMUNOGEN INC IMGN 2021-05-10 15:15:03 UTC -0.304 0.354 1600000
IMMUNOGEN INC IMGN 2021-05-10 14:45:04 UTC -0.304 0.354 1600000
IMMUNOGEN INC IMGN 2021-05-10 14:15:04 UTC -0.304 0.354 1600000
IMMUNOGEN INC IMGN 2021-05-10 13:45:04 UTC -0.304 0.354 1600000
IMMUNOGEN INC IMGN 2021-05-10 13:15:03 UTC -0.304 0.354 1600000
IMMUNOGEN INC IMGN 2021-05-10 12:45:02 UTC -0.304 0.354 1600000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments